Skip to main content
SpringerLink
Log in

Renal Cancer

  • Chapter
Tropical Hemato-Oncology

  • 720 Accesses

Abstract

As the global incidence and mortality of kidney cancer increases, the treatment modalities of renal-cell carcinoma have also progressed over the last decade. There are improved surgical techniques, which aim to preserve renal function for localized cancer, as well as new systemic therapy, that improve treatment outcomes for metastatic cases. The international treatment guidelines are based on best clinical evidence, but in some countries, there is limitation in resources and this has to be accounted for. This is most evident in low-income countries where there are financial restraints as well as a lack of skilled health-care professionals. This chapter aims to address this difficulty by summarizing treatment recommendations for renal-cell carcinoma according to clinical evidence and stratifying treatments according to resource (financial, skill, and logistical) availability. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), which was previously described by the Breast Health Global Initiative.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socio-economic burden of metastatic renal cell carcinoma (mRCC): a literature re-view. Cancer Treat Rev 34:193–205

    Google Scholar 

  2. Naito S, Tomita Y, Rha SY et al (2010) Kidney Cancer Working Group report. Jpn J Clin Oncol 40(suppl 1):51–56

    Article  Google Scholar 

  3. IARC (2014) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 9 Dec 2014

  4. Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 11:171–178

    Article  CAS  PubMed  Google Scholar 

  5. Chiong E, Consigliere D, Esuvaranathan K (2007) Renal tumours: a common incidental finding. Singapore Med J 4(8):495–502

    Google Scholar 

  6. Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 16(6):1611–1623

    Article  Google Scholar 

  7. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 17(3):1853–1862

    Article  Google Scholar 

  8. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  9. Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT et al (2012) Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 13(11):e482–e491

    Article  PubMed  Google Scholar 

  10. Anderson BO, Yip CH, Smith RA et al (2008) Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 113(suppl 8):2221–2243

    Article  PubMed  Google Scholar 

  11. NCCN Clinical Guidelines in Oncology: Kidney Cancer Version 2.2015 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#kidney. Accessed 9 Dec 2014

  12. Blom JH, van Poppel H, Marechal JM et al (2009) Radical nephrectomy with and with-out lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55:28–34

    Article  PubMed  Google Scholar 

  13. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM et al (2012) Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 61(5):972–993

    Article  PubMed  Google Scholar 

  14. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Staehler M, Volpe A. Guidelines on renal cell carcinoma. Uroweb 2013. www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LR.pdf. Accessed 9 Dec 2014

  15. Volpe A, Amparore D, Mottrie A (2013) Treatment outcomes of partial nephrectomy for T1b tumours. Curr Opin Urol 23(5):403–410

    Article  PubMed  Google Scholar 

  16. Van Poppel H, Da Pozzo L, Albrecht W et al (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59:543–552

    Article  PubMed  Google Scholar 

  17. Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 17(9):1227–1233

    Article  Google Scholar 

  18. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175:425–431

    Article  PubMed  Google Scholar 

  19. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrec-tomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 3(58):966–970

    Article  Google Scholar 

  20. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by inter-feron alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659

    Article  CAS  PubMed  Google Scholar 

  21. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076

    Article  PubMed  Google Scholar 

  22. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) Pathology and genetics: tumours of the urinary system and male genital organs. IARC, Lyon, France, p 65

    Google Scholar 

  23. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141

    Article  CAS  PubMed  Google Scholar 

  24. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  CAS  PubMed  Google Scholar 

  25. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon-alfa in meta-static renal-cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  26. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  27. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon-alfa com-pared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 3(56):125–134

    Article  Google Scholar 

  29. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  CAS  PubMed  Google Scholar 

  30. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 3(72):449–456

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, National University Health System, Singapore, Singapore

    Fiona Mei Wen Wu & Edmund Chiong

Authors
  1. Fiona Mei Wen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edmund Chiong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edmund Chiong .

Editor information

Editors and Affiliations

  1. Medical Oncology, Claude-Bernard-Lyon1 University, Lyon, France

    Jean-Pierre Droz

  2. Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Bernard Carme

  3. Service de dermatologie, Centre hospitalier de Cayenne, Cayenne, French Guiana

    Pierre Couppié

  4. Guyane, INSERM CIC 1424, Centre d'Investigation Clinique Antilles, Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Mathieu Nacher

  5. Service d’hémato-oncologie, Hôpital Saint-Louis, Paris, France

    Catherine Thiéblemont

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wu, F.M.W., Chiong, E. (2015). Renal Cancer. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18257-5_41

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18256-8

  • Online ISBN: 978-3-319-18257-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation